Santé Ventures Closes Fifth Fund at 330 Million Dollars to Invest in Early Stage Healthcare and Life Sciences Companies in Austin and Boston

Healthcare innovation just got a major boost.

Santé Ventures, a prominent early-stage investment firm with offices in Austin, Texas, and Boston, Massachusetts, has successfully closed its fifth fund, securing $330 million.

This marks another significant chapter in the firm’s journey of backing transformative healthcare and life sciences companies.

A Continued Focus on Transformative Healthcare

Fund V is set to continue Santé Ventures’ commitment to supporting companies that are reshaping the healthcare landscape.

The firm aims to invest in biotechnology, medical technology, and digitally enabled healthcare companies that tackle pressing medical challenges.

Their focus remains on ventures that can deliver meaningful improvements in patient care, particularly in areas where clinical practices are complex, capital-intensive, or built on outdated models.

Suggested Readings (News continues below)

Van driver admits killing university student in tragic crash outside King’s College London leaving two others injured

SASSA begins paying February 2026 social grants across South Africa as millions of beneficiaries prepare for scheduled payouts

See It Again completes remarkable comeback by winning the World Sports Betting Cape Town Met at Hollywoodbets Kenilworth in Cape Town

Qatar Investment Authority partners with Qatar Development Bank to provide AI compute power to startups in Fund of Funds portfolio while investing in five global venture capital funds

Building on a Track Record of Success

Since its founding in 2006, Santé Ventures has built a strong reputation as a lead venture investor.

The firm has been behind several successful exits, including Laminar (acquired by Johnson & Johnson), Farapulse (Boston Scientific), AbVitro (Bristol Myers Squibb), and Explorys (IBM Corp).

These successes highlight the firm’s expertise in identifying early-stage companies with the potential to make a real difference in healthcare.

Leadership Driving Innovation

Kevin Lalande, the Founding Managing Director and Chief Investment Officer, leads Santé Ventures.

Under his guidance, the firm has grown to manage over $1 billion in capital, investing in companies that develop groundbreaking medical technologies, biotechnologies, and digital healthcare solutions.

Recent notable investments include Healthcare Highways – CerpassRx (Nomi Health), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (MTEM).

New Promotions Mark a Growth Phase

Alongside the launch of Fund V, Santé Ventures announced internal promotions that signal the firm’s ongoing growth.

Dennis McWilliams and Omar Khalil have been elevated to Managing Directors, positioning them to play a larger role in guiding the firm’s next wave of investments.

Looking Ahead

With Fund V now in place, Santé Ventures is poised to continue shaping the future of healthcare.

The firm’s strategy of targeting early-stage companies addressing unmet medical needs ensures that patients and the healthcare system alike will benefit from innovative solutions for years to come.